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Objective radiologic analysis with NIH image software for small peripheral lung cancer
exhibited a good correlation with the histologic classification, pathologic invasiveness, and
postoperative outcome. Patients with tumors that had a ground-glass opacity area of larger than
50% could be candidates for curative limited pulmonary resection.
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This prospective trial of the accuracy of restaging CT, endoscopic ultrasonography with fine-
needle aspiration (EUS-FNA), and fluoro-2-deoxy-D-glucose (FDG)–integrated positron
emission tomography with CT (FDG-PET/CT) in 48 patients with esophageal cancer after
neoadjuvant treatment found that FDG-PET/CT is superior to EUS-FNA and CT for predicting
nodal status and complete responders.
1242 Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of
lung cancer for dose-dependent effect
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The effect of increasing doses of the COX-2 inhibitor celecoxib on lung cancer progression
was evaluated in an orthotopic murine model. Low-dose celecoxib significantly inhibited tumor
progression. Higher doses afforded no additional benefit.
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